儿童骨肉瘤的临床特征和治疗结果：大剂量化疗联合自体造血干细胞移植的作用。
Clinical characteristics and treatment results of pediatric osteosarcoma: the role of high dose chemotherapy with autologous stem cell transplantation.
机构信息
Division of Hematology/Oncology, Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
出版信息
Cancer Res Treat. 2008 Dec;40(4):172-7. doi: 10.4143/crt.2008.40.4.172. Epub 2008 Dec 31.
PURPOSE
In this study, we investigated the clinical characteristics and treatment results of osteosarcoma during the past 7 years, and evaluated the role of high dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT).
MATERIALS AND METHODS
We retrospectively analyzed the clinical data of patients who were diagnosed as osteosarcoma at our center from January, 2000 to December, 2007.
RESULTS
The 5-year overall survival and event-free survival of the patients were 72.6% and 55.9%, respectively. Seventeen (41.5%) patients showed disease progression during treatment or relapse after the end of treatment. The patients who had metastasis at diagnosis or who had a lower grade of necrosis after neoadjuvant chemotherapy showed decreased overall and event-free survival. Four patients received ASCT after HDCT, and 3 of them are alive without disease.
CONCLUSIONS
The patients who relapsed or had refractory osteosarcoma or who had metastasis at diagnosis or a lower grade of necrosis after neoadjuvant chemotherapy showed poor prognosis. HDCT with ASCT could be an alternative treatment option for these patients.
目的
本研究旨在调查过去 7 年中骨肉瘤的临床特征和治疗结果，并评估大剂量化疗（HDCT）联合自体干细胞移植（ASCT）的作用。
材料和方法
我们回顾性分析了 2000 年 1 月至 2007 年 12 月在我中心诊断为骨肉瘤的患者的临床资料。
结果
患者的 5 年总生存率和无事件生存率分别为 72.6%和 55.9%。17 名（41.5%）患者在治疗过程中出现疾病进展或治疗结束后复发。初诊时发生转移或新辅助化疗后肿瘤坏死率较低的患者总生存率和无事件生存率降低。4 例患者在 HDCT 后接受了 ASCT，其中 3 例患者无病存活。
结论
复发或难治性骨肉瘤、初诊时发生转移或新辅助化疗后肿瘤坏死率较低的患者预后较差。HDCT 联合 ASCT 可能是这些患者的一种治疗选择。
Zotero 插件